Objective:In order to explore the impact of corona virus disease 2019(COVID-19)on the hospitalization of children with bronchiolitis and to improve clinicians′ understanding of the characteristics of bronchiolitis during the COVID-19 epidemic.Methods:This was a multicenter clinical study, and the data have been collected from 23 children′s medical centers in China.All the clinical data were retrospectively collected from children with bronchiolitis who were hospitalized at each study center from January 1, 2019 to December 31, 2021.The results included gender, age at hospitalization, length of stay, respiratory syncytial virus(RSV) test results, severity rating, ICU treatment, and the total number of children hospitalized with respiratory tract infection during the same period.The clinical data of children with bronchiolitis in 2019 before COVID-19 epidemic and in 2020、2021 during COVID-19 epidemic were statistically analyzed and compared.Results:According to a summary of data provided by 23 children′s medical centers, there were 4 909 cases of bronchiolitis in 2019, 2 654 cases in 2020, and 3 500 cases in 2021.Compared with 2019, the number of bronchiolitis cases decreased by 45.94% in 2020 and 28.70% in 2021.In 2019, 2020 and 2021, there were no significant differences in gender ratio, age, and duration of hospitalization.Compared with 2019, the ratio of bronchiolitis to the total number of hospitalizations for respiratory tract infection decreased significantly in 2020 and 2021( χ2=12.762, P<0.05; χ2=84.845, P<0.05).The proportion of moderate to severe bronchiolitis cases in both 2020 and 2021 was lower than that in 2019, and the difference was statistically significant ( χ2=4.054, P<0.05; χ2=8.109, P<0.05).There was no statistically significant difference in the proportion of bronchiolitis cases requiring ICU treatment between 2019, 2020, and 2021 ( χ2=1.914, P>0.05).In 2019, a total of 52.60%(2 582/4 909) of children with bronchiolitis underwent RSV pathogen testing, and among them, there were 708 cases with RSV positive, accounting for 28.00%.In 2020, 54.14%(1 437/2 654) of children with bronchiolitis underwent RSV pathogen testing, and there were 403 cases with RSV positive, accounting for 28.04%.In 2021, 66.80%(2 238/3 500) of children with bronchiolitis underwent RSV pathogen testing, and there were 935 cases with RSV positive, accounting for 41.78%.Compared with 2019 and 2020, the RSV positive rate in 2021 showed a significant increase( χ2=99.673, P<0.05; χ2=71.292, P<0.05). Conclusion:During the COVID-19 epidemic, the implementation of epidemic prevention and control measures reduced the hospitalization rate and severity of bronchiolitis, but did not reduce the positive rate of RSV detection.

In order to investigate the species and categorization of Gasterophilus in Ili horse.We analysised the COI gene of the identified Gasterophilus dominant species and constructed NJ phylogenetic tree in the study.The results showed that infection rate was 100％ in total of 16 775 the third phase Gasterophilus instar larvae.Four Gasterophilus species were identified,and showed serious mix infections.Dominant species were Gasterophilus nasalis,its relative dominance were 53.17％,and prefer to live in the cardia,others to irregular live in the pylorus of the horses.COI gene homology of GasterophiIus nasalis,Gasterophilus intestinalis,Gasterophilus pecorum,Gasterophilus haemorrhoidalis (GenBank Accession No.:GU265752.1,KR230402.1,KU578262.1,KT946620.1) were 99％,99％,99％ and 100％ respectively.Phylogenetic analysis results showed that the data were clustered with the Gasterophilus app.which publshed on the GenBank.G.intestinalis and G.haemorrhoidalis cluster together first,and then cluster with G.nasalis,at last all three kinds of Gasterophilus cluster with G.pecorum.When the COI gene is the target,in-group and out-group of the Gasterophilus can forms an independent evolutionary branch.This study provides useful parameters for the classification of Gasterophilus.

Objective To study effect of atypical antipsychotics on glial cell line-derived neurotrophic factor (GDNF) levels in schizophrenia patients.Methods A total of 104 drug-free schizophrenic patients and 70 healthy controls were recruited.All patients were treated with atypical antipsychotic monotherapy.GDNF serumlevels and psychiatric symptoms were assessed at baseline and at 2,4,6 and 8 weeks of treatment.Results Baseline serum GDNF levels were significantly lower in schizophrenic patients than healthy controls (t =5.596,P ＜ 0.001).GDNF levels gradually increased accompanied by a reduction in psychiatric symptoms during antipsychotic therapy (P ＜ 0.01).The levels of GDNF in responders were significantly changed after treatment (P ＜ 0.01),however,no significant change was found in non-responders (P ＞ 0.05).Furthermore,a negative association between GDNF levels after pharmacotherapy and disease duration in schizophrenic subjects could be observed (r =-0.270,P =0.024).Conclusion The present study suggests that GDNF may be involved in the mechanisms of schizophrenia pathogenesis and pharmacological efficacy.

Objective To study effect of atypical antipsychotics on glial cell line-derived neurotrophic factor (GDNF) levels in schizophrenia patients.Methods A total of 104 drug-free schizophrenic patients and 70 healthy controls were recruited.All patients were treated with atypical antipsychotic monotherapy.GDNF serumlevels and psychiatric symptoms were assessed at baseline and at 2,4,6 and 8 weeks of treatment.Results Baseline serum GDNF levels were significantly lower in schizophrenic patients than healthy controls (t =5.596,P ＜ 0.001).GDNF levels gradually increased accompanied by a reduction in psychiatric symptoms during antipsychotic therapy (P ＜ 0.01).The levels of GDNF in responders were significantly changed after treatment (P ＜ 0.01),however,no significant change was found in non-responders (P ＞ 0.05).Furthermore,a negative association between GDNF levels after pharmacotherapy and disease duration in schizophrenic subjects could be observed (r =-0.270,P =0.024).Conclusion The present study suggests that GDNF may be involved in the mechanisms of schizophrenia pathogenesis and pharmacological efficacy.

Objective To summarize the situations and characteristics of adverse drug reactions (ADR)of bevacizumab(Bev)combined with chemotherapy in treatment of advanced colorectal cancer. Methods The medical data of the patients with advanced colorectal cancer who received Bev combined with chemotherapy in Shanxi Tumor Hospital from April 2010 to December 2016 were collected for retrospective analysis. The sexual distinction,age,therapeutic regimen,time of using Bev,types and grades of adverse reactions which were related to chemotherapy and Bev respectively,the time from medication to appearance of ADR,and the patients′outcomes were comparied. Results A total of 83 patients were enrolled in the study. Of them,39 were males and 44 were females. Fifty-eight cases were <65 years old,25 cases were≥65 years old. There were 43 patients with colon cancer and 40 patients with rectal cancer. Forty-five patients received the treatment with Bev combined with first-line chemotherapy,and the number of cases who received mFOLFOX,FOLFIRI and fluorouracil were 18,22 and 5,respectively. Thirty-eight patients received the treatment with Bev combined with second-line chemotherapy,and the number of cases receiving mFOLFOX,FOLFIRI and fluorouracil were 9,19 and 10,respectively. Of 83 patients,71 patients developed totally 152 case-times ADRs which were related to chemotherapy drugs,among them 31 patients developed 31 case-times ADRs related to Bev. The incidences of ADRs associated with chemotherapy drugs and Bev were 85.5% and 37.3%,respectively. The forenamed proportions were 83.1%(152/183)and 16.9%(31/183)respectively in the total case-times of ADRs. The top five incidences of ADRs associated with chemotherapy drugs were bone marrow suppression(59.0%,49/83),nausea and vomiting(51.8%, 43/83),fatigue(19.3%,16/83),peripheral neuritis(15.7%,13/83)and abnormal liver function (10.8%,9/83),successively. The proportions of levels of I,II,III and IV of ADRs were 28.2%(20/71),36.6%(26/71),23.9%(17/71)and 11.3%(8/71),respectively. The highest incidence of ADRs associated with Bev was hypertension(13.3%,11/83),after that the incidences were hemorrhage (12. 0%,10/83),thrombosis(6. 0%,5/83),intestinal perforation(2. 4%,2/83),proteinuria (2.4%,2/83)and wound healing syndrome(1.2%,1/83),successively. The proportions of levels ofⅠ,Ⅱ,ⅢandⅣof ADR were 58.1%(18/31),19.4%(6/31),16.1%(5/31)and 6.5%(2/31), respectively. The ADRs related to the chemotherapy drugs appeared on day 1-115 after medications,the proportion of less than or equal to 3 months were 73.2%(52/71). The ADRs related to Bev appeared on day 5-130 after medications,the proportion of less than or equal to 3 months were 87.1%(27/31). The results of stratification analysis of gender,age(<65 years old and≥65 years old),using time(first-line or second-line chemotherapy),cumulant of Bev(≤6 periods and >6 periods),and combined with different chemotherapy regimens(mFOLFOX,FOLFIRI and fluorouracil)showed that there were no significant differences between the incidences of ADRs related to chemotherapeutic drugs and Bev among the groups of different clinical features. The proportion of levels III and IV ADRs related to chemotherapeutic drugs were higher than those of Bev combining with single drug regimen of 5-FU(P<0.05). There were no significant differences in ADR level distributions of chemotherapeutic drugs and Bev in other clinical features groups (all P>0.05). Conclusions The main ADRs caused by Bev combined with different chemotherapies in treatment of advanced colorectal cancer are ADR related to chemotherapeutic drugs. The ADRs associated with chemotherapeutic drugs and Bev are level Ⅰ-Ⅱ mainly and had better safety.

Objective To summarize the situations and characteristics of adverse drug reactions (ADR)of bevacizumab(Bev)combined with chemotherapy in treatment of advanced colorectal cancer. Methods The medical data of the patients with advanced colorectal cancer who received Bev combined with chemotherapy in Shanxi Tumor Hospital from April 2010 to December 2016 were collected for retrospective analysis. The sexual distinction,age,therapeutic regimen,time of using Bev,types and grades of adverse reactions which were related to chemotherapy and Bev respectively,the time from medication to appearance of ADR,and the patients′outcomes were comparied. Results A total of 83 patients were enrolled in the study. Of them,39 were males and 44 were females. Fifty-eight cases were <65 years old,25 cases were≥65 years old. There were 43 patients with colon cancer and 40 patients with rectal cancer. Forty-five patients received the treatment with Bev combined with first-line chemotherapy,and the number of cases who received mFOLFOX,FOLFIRI and fluorouracil were 18,22 and 5,respectively. Thirty-eight patients received the treatment with Bev combined with second-line chemotherapy,and the number of cases receiving mFOLFOX,FOLFIRI and fluorouracil were 9,19 and 10,respectively. Of 83 patients,71 patients developed totally 152 case-times ADRs which were related to chemotherapy drugs,among them 31 patients developed 31 case-times ADRs related to Bev. The incidences of ADRs associated with chemotherapy drugs and Bev were 85.5% and 37.3%,respectively. The forenamed proportions were 83.1%(152/183)and 16.9%(31/183)respectively in the total case-times of ADRs. The top five incidences of ADRs associated with chemotherapy drugs were bone marrow suppression(59.0%,49/83),nausea and vomiting(51.8%, 43/83),fatigue(19.3%,16/83),peripheral neuritis(15.7%,13/83)and abnormal liver function (10.8%,9/83),successively. The proportions of levels of I,II,III and IV of ADRs were 28.2%(20/71),36.6%(26/71),23.9%(17/71)and 11.3%(8/71),respectively. The highest incidence of ADRs associated with Bev was hypertension(13.3%,11/83),after that the incidences were hemorrhage (12. 0%,10/83),thrombosis(6. 0%,5/83),intestinal perforation(2. 4%,2/83),proteinuria (2.4%,2/83)and wound healing syndrome(1.2%,1/83),successively. The proportions of levels ofⅠ,Ⅱ,ⅢandⅣof ADR were 58.1%(18/31),19.4%(6/31),16.1%(5/31)and 6.5%(2/31), respectively. The ADRs related to the chemotherapy drugs appeared on day 1-115 after medications,the proportion of less than or equal to 3 months were 73.2%(52/71). The ADRs related to Bev appeared on day 5-130 after medications,the proportion of less than or equal to 3 months were 87.1%(27/31). The results of stratification analysis of gender,age(<65 years old and≥65 years old),using time(first-line or second-line chemotherapy),cumulant of Bev(≤6 periods and >6 periods),and combined with different chemotherapy regimens(mFOLFOX,FOLFIRI and fluorouracil)showed that there were no significant differences between the incidences of ADRs related to chemotherapeutic drugs and Bev among the groups of different clinical features. The proportion of levels III and IV ADRs related to chemotherapeutic drugs were higher than those of Bev combining with single drug regimen of 5-FU(P<0.05). There were no significant differences in ADR level distributions of chemotherapeutic drugs and Bev in other clinical features groups (all P>0.05). Conclusions The main ADRs caused by Bev combined with different chemotherapies in treatment of advanced colorectal cancer are ADR related to chemotherapeutic drugs. The ADRs associated with chemotherapeutic drugs and Bev are level Ⅰ-Ⅱ mainly and had better safety.

Objective To investigate the efficacy and safety of Bevacizumab (Bev) combined with chemotherapy protocols in the patients with metastatic colorectal cancer (mCRC).Methods 43 patients with mCRC were treated with Bev combined with various of chemotherapy protocols.The efficacy was assessed based on Response Evaluation Criterion for Solid Tumors (RECIST),and the adverse events were evaluated according to National Cancer Institute-Common Toxicity Criterion for Adverse Events (NCI-CTCAE) 3.0.Results The data of 43 patients (16 males and 27 females) were analyzed.17 patients achieved partial remission (PR),19 patients stable disease (SD) and 7 patients progressive disease (PD).The median progression-free survival (PFS) time was 10.3 months.The major of 3-4 adverse events included leucocytopenia,neutropenic febrile,and nausea/vomiting.Bey-associated adverse events were proteinuria,hypertension,rhinorrhagia,hemorrhagic hemorrhoid,menstrual blood increased,gastrointestinal perforation and venous thrombosis.Conclusions Bey combined with various chemotherapy protocols is more effective for patients with mCRC.Most patients can tolerate the side effects of the combined treatment.The long-term effects of the combined treatment need to be followed up.